gMS-Classifier1 does not predict disability progression in multiple sclerosis
Authorsvan Rossum, Johannis A.
Villar, Luisa M.
Riskind, Peter N.
Freedman, Mark S.
UMass Chan AffiliationsMemorial Multiple Sclerosis Center, UMass Memorial Medical Center
Department of Neurology
Amino Acids, Peptides, and Proteins
Immune System Diseases
Nervous System Diseases
Pathological Conditions, Signs and Symptoms
MetadataShow full item record
AbstractSeveral clinical, immunological and radiological biomarkers have been shown to predict the disease course of multiple sclerosis (MS).One potential serum marker is the gMS-Classifier1, which is composed of IgM anti-Glc antibodies, namely anti-GAGA 2,3,4 and 6. Previous work demonstrated that the gMS-Classifier1 could not predict early conversion to clinically definite MS in a cohort of clinically isolated syndrome (CIS) patients, but predicted Expanded Disability Status Scale (EDSS) progression. Significance, however, was dependent on covariates, and confirmation in an independent study was required. The aim of this study was to test if the gMS-Classifier1 could predict early disability progression in a large multicenter cohort of patients with CIS or relapse-onset MS.
Mult Scler. 2019 Jun;25(7):1010-1011. doi: 10.1177/1352458518798048. Epub 2018 Aug 31. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/41103
Rights© The Author(s), 2018. Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Except where otherwise noted, this item's license is described as © The Author(s), 2018. Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)